Learn More about Lumida ETF
Powered by LumidaWealth.com
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
No Result
View All Result
  • Lumida Wealth
  • Lumida Ledger
  • LUMIDA ETF
  • About Us
Home Lifestyle Health and Longevity

Information Blocking in Healthcare Is Down — But a Stubborn Minority of IT Vendors Keep Doing It Routinely

by Team Lumida
July 13, 2026
in Health and Longevity
Reading Time: 4 mins read
A A
0
doctor holding red stethoscope

Photo by Online Marketing on Unsplash

Share on TelegramShare on TwitterShare on FacebookShare on LinkedinShare on Whatsapp
  • The share of health information exchange organizations reporting instances of potential information blocking dropped from more than 90% in 2019 to 71% in 2025, according to new data from the Office of the National Coordinator for Health Information Technology — a meaningful improvement over six years that the ONC attributes partly to the regulatory framework established by the 21st Century Cures Act (2016) and the information blocking rules that went into effect in 2021; however, the improvement masks a persistent hard core of bad actors: the share of exchanges routinely experiencing blocking has remained unchanged over the entire period.
  • Health IT developers — not hospitals — are the primary information blockers: more than 60% of health information exchanges said IT developers sometimes or routinely hindered health data flow in 2025, compared with about half of hospitals and health systems; approximately 60% said IT developers used fees and pricing to potentially block data sharing, down from over 80% in 2019; the pattern suggests that proprietary data lock-in remains a business model for a subset of health IT vendors despite federal prohibition.
  • The enforcement picture has been weak: the Trump administration has issued notices of nonconformity to potential information blockers, but as of March 2026 the federal government had not levied any penalties or enforcement actions despite the rules having been in effect since 2021 — National Coordinator Dr. Thomas Keane told lawmakers in March that action was coming, with IT developers facing potential loss of ONC health IT certification and fines from the HHS Office of Inspector General.
  • The ONC’s analysis carries a policy implication: since most information blocking is concentrated among a small group of repeat offenders (“fewer specific entities may be engaged in potential information blocking, and some share of those entities are consistently doing so routinely”), targeted enforcement against a small number of high-frequency blockers could have an outsized impact on overall data exchange — a precision enforcement strategy rather than broad regulatory pressure.

What Happened?

The ONC released new data showing improvement in health information blocking trends from 2019 to 2025: the share of health information exchanges reporting any potential blocking fell from over 90% to 71%. But the analysis also reveals that routine blocking by a minority of IT developers and hospitals has not declined — the same roughly one-third of exchanges that experienced routine IT developer blocking in 2019 still experienced it in 2025. The federal government has yet to levy any fines or enforcement actions despite rules that have been in effect for five years.

Why It Matters?

Information blocking is not a technical problem — it is a business model problem. Health IT vendors that have built proprietary data ecosystems have financial incentives to make it difficult for patients and providers to move data to competing systems. The 21st Century Cures Act tried to address this by prohibiting blocking and establishing a penalty regime, but five years of non-enforcement have undermined deterrence. The consequence is real: patients whose records are fragmented across systems that don’t communicate face worse care coordination, duplicate testing, and medication errors that more seamless data exchange would prevent. The concentration of blocking among IT vendors — rather than hospitals — points to the EHR and health IT industry as the primary target for enforcement action.

What’s Next?

The ONC and HHS OIG have signaled that enforcement is coming. The first actual penalty levied against an information blocker — whether an IT developer losing its ONC certification or a firm being fined by the OIG — will be the signal that the regulatory framework has teeth. Watch for whether the Trump administration’s stated commitment to information blocking enforcement materializes in specific actions against named vendors before the end of 2026. The TEFCA (Trusted Exchange Framework and Common Agreement) rollout, which the ONC is separately accelerating, provides the interoperability infrastructure that makes blocking harder and less valuable as a competitive strategy.

Source: Healthcare Dive

Previous Post

Bitcoin Sits Out the War: Crypto Holds Near $63,800 as Gold, Oil, Stocks, and Bonds All Sell Off on Fourth Iran Strike

Next Post

The Real AI Jobs Threat Isn’t Unemployment — It’s a Coming Labor Shortage That AI May Need to Fill

Recommended For You

Novo Nordisk’s $10 Billion Cardiovascular Bet Fails — Ziltivekimab Misses Heart Attack and Stroke Endpoint, Stock Drops 10.5%

by Team Lumida
8 hours ago
Novo Nordisk Q2 2024 Earnings Highlights

Novo Nordisk's experimental drug ziltivekimab — a monthly IL-6 inhibitor injection targeting cardiovascular disease, chronic kidney disease, and inflammation in a market Jefferies estimates at $10B+ annually —...

Read more

Trump Administration to End $3.6 Billion Medicare Drug Premium Subsidy — Seniors Face Higher Part D Costs in 2027

by Team Lumida
2 days ago
Supreme Court Signals It Will Strike Down Trump’s Birthright Citizenship Order

The Trump administration will not renew the Part D Low Income Premium Subsidy program after 2026, eliminating $3.6 billion in annual payments to insurers that have been holding...

Read more

80% of People Are Deficient in Essential Vitamins — Here Are the 10 You Actually Need and Where to Get Them

by Team Lumida
4 days ago
oranges, peas, and limes on a wooden table

Most people are not getting enough of the 13 essential vitamins their bodies require — here is a practical guide to the most critical nutrients, what they do,...

Read more

Whoop Enters Clinical Care With Joint Replacement Recovery Pilot — Can Wearable Biometrics Reduce Opioids and Speed Recovery?

by Team Lumida
2 weeks ago
a close up of a human skull on a black background

Whoop and surgical software company Kinomatic have launched a 12-week pilot program called Restore across three California orthopedic clinics to test whether continuous biometric monitoring — heart rate...

Read more

$399 Signal Ring Claims to Replace the Blood Pressure Cuff — No Calibration, No Subscription, Clinical Trial at Stanford

by Team Lumida
2 weeks ago
Fingers hold a black smart ring with circuits visible.

Vital Signals, a three-year-old startup, has launched a $399 Signal Ring that claims to track blood pressure as accurately as a traditional arm cuff — without requiring any...

Read more

Novo’s Obesity Pill Commands 89% Market Share — Lilly’s Foundayo Captures Just 11% After Three Months on Market

by Team Lumida
2 weeks ago
Novo’s Obesity Pill Commands 89% Market Share — Lilly’s Foundayo Captures Just 11% After Three Months on Market

Novo Nordisk's Wegovy pill has seized 89% of new oral obesity pill prescriptions since its January 2026 launch, leaving Eli Lilly's Foundayo — launched in April — with...

Read more

Novo Nordisk Squeezes Suppliers for Discounts as Eli Lilly Eats Its Lunch in the Obesity Drug Market

by Team Lumida
4 weeks ago
Novo Nordisk Q2 2024 Earnings Highlights

Novo Nordisk has written to suppliers seeking price discounts to protect its cost base as it fights to claw back market share lost to Eli Lilly in the...

Read more

Medicare Launches $50/Month Weight-Loss Drug Coverage Today — With Caveats

by Team Lumida
1 month ago
GLP-1 Drugs Are Triggering a Returns Crisis for America’s Apparel Retailers

Medicare's "Bridge" program kicks off July 1, offering Wegovy and Zepbound to 12.5–20 million eligible seniors at a $50 monthly copay — down from up to $450 cash...

Read more

FDA Reverses Rejection of Regenxbio Gene Therapy for Fatal Rare Disease

by Team Lumida
1 month ago
FDA Reverses Rejection of Regenxbio Gene Therapy for Fatal Rare Disease

The FDA agreed to reverse its rejection of Regenxbio's Navsunli gene therapy for Hunter syndrome — the third rare-disease drug reversal under new FDA leadership, marking a retreat...

Read more

Nvidia Partners With Abridge to Build an AI Model Trained on Real Doctor-Patient Conversations

by Team Lumida
2 months ago
Nvidia’s AI Demand Surge: Hon Hai Ramps Up Server Production

Nvidia and AI medical note-taking startup Abridge are jointly developing a clinical AI model trained on de-identified doctor-patient conversations, using Nvidia's open Nemotron models as a base —...

Read more
Next Post
AI Investment Boom: How Tech Giants Are Leading the Charge

The Real AI Jobs Threat Isn't Unemployment — It's a Coming Labor Shortage That AI May Need to Fill

Nvidia CEO Reveals Secrets Behind AI Domination Amidst Fierce Competition

Wall Street to AI Hyperscalers: Slow Down — $75B From Nvidia, SpaceX, and Amazon Is Testing the Bond Market's Limits

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related News

a close-up of a screen

Is the Market Bubble Peaking? Insights from a Black Swan Expert

July 19, 2024
flag hanging on pole

JPMorgan’s $40 Billion Indian Bond Bet:

June 20, 2024
Nvidia CEO Reveals Secrets Behind AI Domination Amidst Fierce Competition

Nvidia Maintains Distance from Crypto, Halts Arbitrum Partnership Announcement

April 25, 2025

Subscribe to Lumida Ledger

Browse by Category

  • Lifestyle
    • Family Office
    • Health and Longevity
    • Next Gen Wealth
    • Trust, Tax, and Estate
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Latest
    • Macro
    • Markets
    • Real Estate
  • Research
    • Trackers
  • Themes
    • Aging & Longevity
    • AI
    • Biotech
    • CRE
    • Cybersecurity
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
    • Software
Facebook Twitter Instagram Youtube TikTok LinkedIn
Lumida News

Premium insights to help you invest beyond the ordinary. Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser

CATEGORIES

  • Aging & Longevity
  • AI
  • Alt Assets
  • Biotech
  • CRE
  • Crypto
  • Cybersecurity
  • Digital Assets
  • Equities
  • Family Office
  • Health and Longevity
  • Latest
  • Legacy Brands
  • Lifestyle
  • Macro
  • Markets
  • News
  • Next Gen Wealth
  • Nuclear Renaissance
  • Private Credit
  • Real Estate
  • Software
  • Themes
  • Trackers
  • Trust, Tax, and Estate

BROWSE BY TAG

AI AI chips Amazon Apple Artificial Intelligence Banking Bitcoin China Commercial Real Estate CPI Crypto data centers Donald Trump EARNINGS ELON MUSK ETF Ethereum Federal Reserve financial services generative AI Goldman Sachs Google India Inflation Intel Interest Rates Investment Strategy Japan Jerome Powell JPMorgan Markets Meta Microsoft Nasdaq Nvidia OpenAI private equity S&P 500 SEC stock market Tech Stocks tesla Trump Wells Fargo Whale Watch

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018

No Result
View All Result
  • Home
  • Earnings
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018